CT7001
Sponsors
Carrick Therapeutics Limited, Pfizer Inc.
Conditions
Advanced Solid MalignanciesAdvanced or Metastatic Breast CancerBreast Cancer
Phase 1
Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies
CompletedNCT03363893
Start: 2017-11-14End: 2022-12-15Updated: 2025-11-12
A Phase 1b/2 Open-Label Study of Samuraciclib in Combination with Elacestrant in Participants with Metastatic or Locally Advanced Hormone-Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
Active, not recruitingCTIS2023-503846-30-00
Start: 2023-10-10Target: 48Updated: 2026-01-27
C4891024 - TACTIVE-U: AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B/2, OPEN-LABEL UMBRELLA STUDY TO INVESTIGATE TOLERABILITY, PK, AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT (ARV-471/PF-07850327), AN ORAL PROTEOLYSIS TARGETING CHIMERA, IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS AGED 18 AND OLDER WITH ER+ ADVANCED OR METASTATIC BREAST CANCER, SUB-STUDY C (ARV-471 IN COMBINATION WITH SAMURACICLIB)
CompletedCTIS2023-507125-41-00
Start: 2024-03-25End: 2025-11-26Target: 48Updated: 2025-11-28